Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

PD-1 (Programmed cell death 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

›

PD-1 overexpression	HER2 Positive Breast Cancer	PD-1 overexpression	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PD-1 overexpression	Peripheral T-cell Lymphoma	PD-1 overexpression	Peripheral T-cell Lymphoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-1 underexpression	Hodgkin Lymphoma	PD-1 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-1 elevation	Renal Cell Carcinoma	PD-1 elevation	Renal Cell Carcinoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
PD-1 overexpression	Diffuse Large B Cell Lymphoma	PD-1 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
PD-1 expression	Bladder Cancer	PD-1 expression	Bladder Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
PD-1 overexpression	Prostate Cancer	PD-1 overexpression	Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-1 overexpression	Cutaneous T-cell Lymphoma	PD-1 overexpression	Cutaneous T-cell Lymphoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-1 expression	Urothelial Cancer	PD-1 expression	Urothelial Cancer	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3
PD-1 overexpression	B Acute Lymphoblastic Leukemia	PD-1 overexpression	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PD-1 expression	Renal Cell Carcinoma	PD-1 expression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3